ClinicalTrials.gg
RecruitingNCT05764044AddChemoUpdated Jul 30, 2024

Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer

A Phase 3 interventional study of cisplatin, gemcitabine and Follow-up in Cervical Cancer, Cervix Cancer and Cervix Neoplasm, sponsored by Hospital do Coracao. Recruiting at 26 sites in Brazil. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-07-30.

Sponsored by Hospital do Coracao · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
365
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies testing cisplatin in Uterine Cervical Neoplasms — 10 open to participants now, 11 under way, 3 of them phase 3. Cisplatin · Uterine Cervical Neoplasms.

Planned enrollment
10th of 73
365 · median 50
Started
2024
with 1 other
Phase 3
20 of 80
3 open now
Primary completion
2026-12
later than 5 of 10 live
Registered
76th of 80
by date

Among the 80 studies testing cisplatin in Uterine Cervical Neoplasms, this one is the 10th largest by planned enrollment of the 73 interventional ones that give a count, is one of 2 that started in 2024, is one of 20 in phase 3, reaches primary completion later than 5 of the 10 other live ones, and was the 76th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

10 of the 80 studies testing cisplatin in Uterine Cervical Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing cisplatin in Uterine Cervical Neoplasms, or all of them as a file.
02

Study summary

This study hypothesizes that patients who persist with cell-free human papillomavirus deoxyribonucleic acid (cfHPV-DNA) plasma expression at the end of standard treatment, can derive the benefit of using adjuvant chemotherapy in locally advanced cervical cancer (CC). After standard treatment based on concomitant chemoradiotherapy regime, a qualitative and quantitative research of cfHPV-DNA in plasma of patients will be conducted. Patients who have positive research for plasma cfHPV-DNA at the end of chemoradiotherapy treatment will be randomized to receive two additional cycles of adjuvant chemotherapy or observation. Patients will be followed with conduction of computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every four months.

Read the detailed description

A prospective, randomized, multicenter, national, superiority, parallel, clinical trial, design to evaluate the use of adjuvant chemotherapy in patients with locally advanced cervical cancer selected by cfDNA-HPV biomarker. Patients will be randomized by stratified randomization process to belong to one of the groups: control (Group B) or intervention (Group C), emphasizing homogeneity of risk factors between them. A randomized list will be generated by using a suitable software, using variable size blocks (2 or 4), with stratification for site and staging. The confidentiality of the randomization list will be maintained through an automated, centralized, Internet-based randomization system, available 24 hours a day (RedCap). Selected patients must receive standard treatment based on concomitant chemoradiotherapy regime, with dose of radiation of 40-50 greys (Gy) (considering additional boost of 10-15 Gy in lymph nodes, radiologically or surgically, compromised) and brachytherapy of 30-40 Gy and cisplatin 40mg/m2 weekly. After four weeks of the end of treatment, a qualitative and quantitative research of cfHPV-DNA in plasma of patients will be conducted. Those with a negative qualitative research result will leave the study. Patients who have positive research for plasma 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 73, 82 cfHPV-DNA at the end of chemoradiotherapy treatment will be randomized to receive two additional cycles of adjuvant chemotherapy or observation. In those cases in which the duration of radiochemotherapy treatment exceeds 84 days, patients must undergo imaging examination (chest, abdomen and pelvis CT) in order to exclude pre-randomization metastatic disease. Patients will be followed with conduction of computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every four months.

03

Conditions studied

  • Cervical Cancer
  • Cervix Cancer
  • Cervix Neoplasm

Keywords

  • Human papillomavirus
  • HPV
  • Cervical cancer
  • Circulating free DNA
  • Adjuvant chemotherapy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IB3 to IVA will be included prospectively.
  • Previous standard treatment based on concomitant chemoradiotherapy regimen.
  • performance status score ≥70, with estimated ≥12 weeks,
  • Immunocompetent,
  • Positive research for types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 73, 82 cfHPV-DNA in plasma at the end of chemoradiotherapy,
  • Proper hematological, liver and kidney functions. Inclusion criteria will include absolute neutrophils count ≥1.5 x 109/L, ≥100 x 10/L, serum ≤ 2.0 x (ULN), calculated ≥50 mL/min and (ALT), aspartate aminotransferase (AST) and alkaline phosphatase ≤ 2.5 x ULN.
  • Patients of were obligated to use an approved method during and for 3 months after the study;
  • Agree with research procedures, by signing the Form (ICF).

Exclusion criteria

Exclusion Criteria:

  • Previous cervical cancer or other ,
  • Pregnant women,
  • Inability to perform concurrent cisplatin based-chemoradiotherapy.
  • Tumors containing different HPV genotypes
  • Absence of anatomopathological examination to prove the diagnosis and/or staging examinations.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
365 participants (estimated)

Study arms

  • Other
    Control Arm (Standard of Care)

    Patients will be followed with plasma cfDNA-HPV, computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every four months.

    Other: Follow-up

  • Experimental
    Experimental Arm

    Receive two cycles of cisplatin-based adjuvant chemotherapy 50mg/m2 D1 and gemcitabine 1000mg/m2 D1 and D8 at every 21 days. After that, patients will be followed with plasma cfDNA-HPV, computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every four months.

    Drug: cisplatin, gemcitabine · Other: Follow-up

Interventions

  • Drugcisplatin, gemcitabine

    Drug pages: CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · GemcitabineStudies of GemcitabineGemcitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Two additional cycles of cisplatin-based adjuvant chemotherapy 50mg/m2 D1 and gemcitabine 1000mg/m2 D1 and D8 at every 21 days.

  • OtherFollow-up

    Patients will be followed with plasma cfDNA-HPV, computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every four months.

06

What researchers measure

Primary outcomes

  1. Progression free survival

    Progression-free survival will be calculated from the date of randomization until the date of progression, whether local or distant, or death.

    Time frame: 120 days

Secondary outcomes

  1. Overall survival

    Pverall survival will be calculated from the date of randomization until death or last follow-up. Follow-up will be updated at each consultation and the following possibilities will be considered: living without disease, living with disease, death from cancer, death from another cause and loss of follow-up.

    Time frame: 120 days

  2. Overall response rate

    Response assessment will be performed using RECIST 1.1 (2009) criteria through pelvic MRI. Thus, complete response (CR) will be considered the disappearance of all lesions. Partial response (PR), reduction (30%) in the sum of the largest diameters of target lesions, when compared to the initial examination. Disease progression (PD): increase (20%) in the sum of the largest diameters of the lesions, when compared to the initial examination or the appearance of new lesions. Stable disease: does not meet criteria for PR or PD.

    Time frame: 120 days

  3. Quality of life measures (EORTC QLQ-C30 and QLC-CX24)

    Generic quality of life measures (EORTC QLQ-C30) will be assessed during medical consultations in this clinical study, considering that this questionnaire alone does not adequately assess specific treatment issues that affect the quality of life of women with cervical cancer, a QLQ-CX24 add-on module will also be applied. All questionnaires used in this study are self-administered, however, in those cases where the ability to understand, little education/illiteracy is considered low or when telephone monitoring is in force, the tests will be applied by the researchers, who will seek to read all the questions and help mark answers.

    Time frame: 21 to 120 days

  4. Toxicity according to the Common Terminology Criteria for Adverse Events v.5.0

    Toxicity will be classified according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (2017). Hematological (anemia, neutropenia, thrombocytopenia and febrile neutropenia), gastrointestinal (diarrhea, nausea and vomiting), renal (serum creatinine changes) and hepatic (AST and ALT changes) toxicities will be evaluated. Grade 1 and 2 toxicities, together, were considered mild and grade 3 and 4 toxicities were considered severe.

    Time frame: 7 to 120 days

07

Study locations

7 of 26 sites recruiting
  • Centro Integrado de Pesquisa da Amazônia, CINPAM
    Manaus, AM 69.020-030, Brazil
    Recruiting
  • Hospital Samur
    Vitória Da Conquista, BA 45.023-145, Brazil
    Not yet recruiting
  • Hospital de Base do Distrito Federal
    Brasília, DF 70.335-900, Brazil
    Not yet recruiting
  • Hospital Evangélico de Cachoeiro de Itapemirim
    Cachoeiro De Itapemirim, ES 29.308-065, Brazil
    Not yet recruiting
    • Narelle Parmanhani · Contactnarelle@iosc.com.br · (28) 3522-5095
    • Sabina Aleixo · Principal investigator
  • Hospital do Câncer de Muriaé
    Muriaé, MG 36.888-233, Brazil
    Recruiting
  • Centro de Oncologia de Cascavel, CEONC
    Cascavel, PR 85.803-760, Brazil
    Not yet recruiting
  • União Oeste Paranaense de Estudos e Combate ao Câncer, UOPECCAN
    Cascavel, PR 85.810-031, Brazil
    Not yet recruiting
  • Centro Integrado de Oncologia de Curitiba, CIONC
    Curitiba, PR 80810-050, Brazil
    Not yet recruiting
  • Instituto Nacional do Câncer, INCA
    Rio de Janeiro, RJ 20.220-410, Brazil
    Recruiting
  • Liga Norte Riograndense Contra o Câncer
    Natal, RN 59.062-000, Brazil
    Not yet recruiting
  • Centro Oncologico de Roraima, CECOR
    Boa Vista, RR 69.304-015, Brazil
    Not yet recruiting
  • Hospital Tacchini
    Bento Gonçalves, RS 95.700-084, Brazil
    Not yet recruiting
  • Hospital Geral de Caxias do Sul
    Caxias Do Sul, RS 95.070-561, Brazil
    Not yet recruiting
    • Ramone Bertussi · Contactrabertus@ucs.br · (54) 3218-7328
    • Janaina Brollo · Principal investigator
  • Hospital Bruno Born
    Lajeado, RS 95.900-010, Brazil
    Not yet recruiting
  • Centro Gaúcho Integrado Hospital Mãe de Deus
    Porto Alegre, RS 90.850- 170, Brazil
    Not yet recruiting
  • Catarina Pesquisa Clínica
    Itajaí, SC 88.301-220, Brazil
    Not yet recruiting
  • Hospital Unimed
    Joinville, SC 89.204-061, Brazil
    Recruiting
  • Centro de Atenção Integral a Saúde da Mulher, CAISM
    Campinas, SP 13.083-881, Brazil
    Not yet recruiting
  • Hospital do Amor
    Jales, SP 15.706-396, Brazil
    Not yet recruiting
  • Hospital do Coração - Research Institute
    Sao Paulo, SP 04.005-000, Brazil
    Recruiting
    • Michelle S Almeida, PhD · Contactmalmeida@hcor.com.br · (11) 999112805
    • Michelle S Almeida, PhD · Principal investigator
  • Hospital da Mulher - SECONCI
    São Paulo, SP 01.206-001, Brazil
    Recruiting
  • Instituto Brasileiro de Combate ao Câncer, IBCC São Camilo
    São Paulo, SP 04.015-070, Brazil
    Not yet recruiting
  • Hospital São Paulo, Unifesp
    São Paulo, SP 04.024-002, Brazil
    Not yet recruiting
    • Vinicius Agibert · Contactv.agibert09@gmail.com
    • Hakaru Tadokoro · Principal investigator
    • Vinicius Agibert · Sub investigator
  • Hospital Santa Marcelina
    São Paulo, SP 08.270-120, Brazil
    Recruiting
  • Centro de Estudos e Pesquisa de Hematologia, CEPHO
    São Paulo, SP 09.060-650, Brazil
    Not yet recruiting
  • Instituo de Câncer Brasil, ICB
    Taubate, SP 12.030-200, Brazil
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data could be shared after reasonable request of the principal investigator.

Supporting information: Study protocol

Time frame: After study completion.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.

Of 53 non-industry phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 107. This study's planned 33 months is below that.

Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2023
First posted
Mar 10, 2023
StartActual
Mar 27, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05764044
Lead sponsor
Hospital do Coracao
Responsible party
Sponsor
First posted
Mar 10, 2023
Start date
Mar 27, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 30, 2024

Study contacts

Michelle S Almeida, PhD
Contact
malmeida@hcor.com.br
11 999112805
Rachel H Machado, MCS
Contact
rhelena@hcor.com.br
11 30536611 ext. 8220

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cisplatin · Gemcitabine

Start the discussion